ESTRO 2025 - Abstract Book

S904

Clinical - Haematology

ESTRO 2025

Conclusion: The RESTART protocol of RT bridging and early cRT post-CAR-T in LBCL according to pre-defined criteria is feasible. The overall response rate, PFS and OS are encouraging and no unexpected toxicity was observed.

Keywords: Large B-cell lymphoma, CAR T-cells, Radiotherapy

References: 1. Kuhnl A et al. A national service for delivering CD19 CAR-T in large B-cell lymphoma - The UK real-world experience. Br J Haematol. 2022; 198(3):492-502. 2. Pinnix CC et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020; 4(13):2871–2883. 3. Kuhnl A et al. Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. Br J Haematol. 2024; 205(2):483-494. 4. Saifi O et al. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023; 108(11):2982–2992.

3593

Digital Poster Results of cutaneous lymphomas treated with radiotherapy Gemma Calvet, Maria Magdalena Piedra, Josep Isern, Jady Vivian Rojas, Antonio Vila, Ana Maria Soto-Cambres, Eugenia Otero, Saba Rabi, Scarlet Marie Crespo, Andrea Ejimeno, Belén Sopena, Gemma Sancho